Share on LinkedInShare on LinkedIn

ARTICLE · 28 FEBRUARY 2022

Inventive Step At The EPO – Plausibility And Post-Published Evidence (G2/21)

Boult Wade Tennant LLP
Boult Wade Tennant LLP
Contributor
Boult Wade Tennant LLP

Boult Wade Tennant LLP

Boult is a top-tier European firm specializing in IP advice and solutions for both domestic and...

View firm profile
Explore more from Boult Wade Tennant LLP

European patent No. 2 484 209 owned by Sumitomo Chemical Company, Limited was opposed by Syngenta Limited on multiple grounds including lack of inventive step.

United KingdomIntellectual Property

The Enlarged Board of Appeal of the European Patent Office has been challenged with a new referral (G2/21) concerning the admissibility of post-published evidence for the assessment of inventive step. The outcome of this referral could have significant consequences for the assessment of patentability at the European Patent Office, particularly for inventions in the fields of biotechnology, life sciences and chemistry.

Background
European patent No. 2 484 209 owned by Sumitomo Chemical Company, Limited was opposed by Syngenta Limited on multiple grounds including lack of inventive step. The Opposition Division rejected the opposition and upheld the patent. The decision was appealed (T0116/18).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from